HRP20180436T1 - Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima - Google Patents

Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima Download PDF

Info

Publication number
HRP20180436T1
HRP20180436T1 HRP20180436TT HRP20180436T HRP20180436T1 HR P20180436 T1 HRP20180436 T1 HR P20180436T1 HR P20180436T T HRP20180436T T HR P20180436TT HR P20180436 T HRP20180436 T HR P20180436T HR P20180436 T1 HRP20180436 T1 HR P20180436T1
Authority
HR
Croatia
Prior art keywords
amisulpride
intended
accordance
vomiting
therapy
Prior art date
Application number
HRP20180436TT
Other languages
English (en)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Nicola Cooper
Gabriel Fox
Original Assignee
Acacia Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180436(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Limited filed Critical Acacia Pharma Limited
Publication of HRP20180436T1 publication Critical patent/HRP20180436T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

1. Amisulprid, naznačen time što je namijenjen upotrebi u terapiji mučnine, povraćanja i podražaja na povraćanje uzrokovanih opijatima.
2. Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je opijat morfin.
3. Amisulprid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se primjenjuje intravenskom, intramuskularnom ili supkutanom injekcijom.
4. Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se primjenjuje rektalnom, intranazalnom, bukalnom, oralnom, transdermalnom, sublingvalnom ili inhalacijskom primjenom.
5. Amisulprid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je subjekt terapije čovjek.
6. Amisulprid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je u obliku jedinične doze koja sadrži manje od 50 mg amisulprida.
7. Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što jedinična doza sadrži 1 do 35 mg amisulprida.
8. Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što se jediničnu dozu od 1 do 35 mg daje jednom ili dvaput dnevno ljudskom subjektu.
9. Amisulprid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je u obliku prihvatljive farmaceutske soli.
10. Amisulprid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen upotrebi u kombinaciji s drugim antiemetičkim lijekom.
11. Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je drugi antiemetički lijek antagonist 5HT3.
12. Amisulprid, namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je antagonist 5HT3 ondansetron.
13. Amisulprid, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što subjekt terapije pokazuje akutne simptome.
HRP20180436TT 2010-03-11 2018-03-14 Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima HRP20180436T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
EP14173186.9A EP2796171B1 (en) 2010-03-11 2011-03-10 Use of amisulpride for treating opiated-induced nausea and vomiting

Publications (1)

Publication Number Publication Date
HRP20180436T1 true HRP20180436T1 (hr) 2018-05-04

Family

ID=42136792

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20140745AT HRP20140745T1 (hr) 2010-03-11 2014-08-01 Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja
HRP20140744AT HRP20140744T1 (hr) 2010-03-11 2014-08-01 Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja
HRP20180436TT HRP20180436T1 (hr) 2010-03-11 2018-03-14 Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HRP20140745AT HRP20140745T1 (hr) 2010-03-11 2014-08-01 Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja
HRP20140744AT HRP20140744T1 (hr) 2010-03-11 2014-08-01 Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja

Country Status (27)

Country Link
US (11) US9084765B2 (hr)
EP (3) EP2544657B1 (hr)
JP (2) JP5886213B2 (hr)
KR (1) KR101738201B1 (hr)
CN (1) CN102892407B (hr)
AU (1) AU2011225898B2 (hr)
BR (1) BR112012022746B1 (hr)
CA (1) CA2792392C (hr)
CY (3) CY1115487T1 (hr)
DK (3) DK2567690T3 (hr)
EA (1) EA030335B1 (hr)
ES (3) ES2496099T3 (hr)
GB (1) GB201004020D0 (hr)
HK (1) HK1179152A1 (hr)
HR (3) HRP20140745T1 (hr)
HU (1) HUE037088T2 (hr)
IL (1) IL221746A (hr)
LT (1) LT2796171T (hr)
MX (3) MX2012010411A (hr)
NO (1) NO2796171T3 (hr)
NZ (1) NZ602279A (hr)
PL (3) PL2796171T3 (hr)
PT (3) PT2796171T (hr)
RS (3) RS57032B1 (hr)
SI (3) SI2796171T1 (hr)
SM (2) SMT201400127B (hr)
WO (1) WO2011110854A2 (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
US10761020B2 (en) 2015-09-02 2020-09-01 California Institute Of Technology Method and apparatus for the spectroscopic detection of low concentrations of hydrogen sulfide gas
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
WO2020247603A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
MX2023000283A (es) 2020-07-06 2023-02-09 Acacia Pharma Ltd Terapia de nausea y vomito post-operatorio.
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
NZ570039A (en) 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
EP1988883A1 (fr) * 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
US20130022688A1 (en) 2013-01-24
PT2796171T (pt) 2018-04-24
US20200093792A1 (en) 2020-03-26
AU2011225898B2 (en) 2014-07-03
US20180353473A1 (en) 2018-12-13
BR112012022746A2 (pt) 2016-07-05
US8686019B2 (en) 2014-04-01
JP2016028090A (ja) 2016-02-25
US20210228543A1 (en) 2021-07-29
HRP20140744T1 (hr) 2014-09-26
PT2567690E (pt) 2014-09-03
IL221746A (en) 2017-03-30
US20170087128A1 (en) 2017-03-30
RS53467B (en) 2014-12-31
CY1115485T1 (el) 2017-01-04
HRP20140745T1 (hr) 2014-09-26
CA2792392C (en) 2018-06-19
SI2567690T1 (sl) 2014-12-31
PL2544657T3 (pl) 2014-10-31
WO2011110854A2 (en) 2011-09-15
JP5886213B2 (ja) 2016-03-16
CA2792392A1 (en) 2011-09-15
EP2796171B1 (en) 2018-01-31
US9545426B2 (en) 2017-01-17
BR112012022746B1 (pt) 2021-09-28
RS57032B1 (sr) 2018-05-31
US20180042896A1 (en) 2018-02-15
CY1115487T1 (el) 2017-01-04
PT2544657E (pt) 2014-09-03
DK2567690T3 (da) 2014-08-11
ES2665418T3 (es) 2018-04-25
SI2796171T1 (en) 2018-05-31
LT2796171T (lt) 2018-05-10
NZ602279A (en) 2014-08-29
US9084765B2 (en) 2015-07-21
EP2567690A1 (en) 2013-03-13
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10
US20150335616A1 (en) 2015-11-26
JP6279526B2 (ja) 2018-02-14
ES2496092T3 (es) 2014-09-18
SI2544657T1 (sl) 2014-12-31
KR20130045241A (ko) 2013-05-03
JP2013522181A (ja) 2013-06-13
EP2796171A1 (en) 2014-10-29
NO2796171T3 (hr) 2018-06-30
CN102892407A (zh) 2013-01-23
US20130022689A1 (en) 2013-01-24
US9119836B2 (en) 2015-09-01
US20230144973A1 (en) 2023-05-11
MX370629B (es) 2019-12-18
DK2796171T3 (en) 2018-05-07
US20220296570A1 (en) 2022-09-22
US10525033B2 (en) 2020-01-07
EA030335B1 (ru) 2018-07-31
SMT201400127B (it) 2015-05-05
CY1120170T1 (el) 2018-12-12
EP2544657B1 (en) 2014-07-16
EA201290833A1 (ru) 2013-09-30
US9889118B2 (en) 2018-02-13
HUE037088T2 (hu) 2018-08-28
EP2567690B1 (en) 2014-07-16
MX2019015396A (es) 2020-02-07
DK2544657T3 (da) 2014-08-11
GB201004020D0 (en) 2010-04-21
ES2496099T3 (es) 2014-09-18
AU2011225898A1 (en) 2012-10-04
CN102892407B (zh) 2016-03-23
MX2012010411A (es) 2012-11-30
KR101738201B1 (ko) 2017-05-19
RS53466B (en) 2014-12-31
EP2544657A2 (en) 2013-01-16
US10085970B2 (en) 2018-10-02
US20140147517A1 (en) 2014-05-29
PL2567690T3 (pl) 2014-11-28
SMT201400126B (it) 2015-05-05
HK1179152A1 (zh) 2013-09-27

Similar Documents

Publication Publication Date Title
HRP20180436T1 (hr) Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2016028090A5 (hr)
JP2016501828A5 (hr)
GB201111485D0 (en) Drug composition and its use in therapy
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
NZ625440A (en) Anti-cxcr1 compositions and methods
MY194947A (en) Intranasal pharmaceutical dosage forms comprising naloxone
GB2495676A (en) Use of binders for manufacturing storage stable formulations
WO2012007159A3 (en) Novel gastro-retentive dosage forms
AR052880A1 (es) Metodo para tratar dolor visceral
HRP20140592T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
NZ576424A (en) Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
RU2015135843A (ru) Терапевтическое средство от грыжи межпозвоночного диска
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
NZ596161A (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2007145863A3 (en) Sustained release formulation of naltrexone
PT2379066E (pt) Uso de antagonistas opioides para a preparação de um medicamento no tratamento das doenças degenerativas da retina
WO2009019693A3 (en) Analgesic effect of jasmonate derivatives